Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
48
GRCE Quote, Financials, Valuation and Earnings
Last price:
$3.43
Seasonality move
:
-16.02%
Day range:
$3.36 - $3.48
52-week range:
$1.75 - $4.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.85x
Volume:
130.1K
Avg. volume:
55.7K
1-year change:
-16.79%
Market cap:
$53.7M
Revenue:
--
EPS (TTM):
-$0.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GRCE
Grace Therapeutics, Inc.
|
-- | -$0.25 | -- | -22.47% | $11.74 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GRCE
Grace Therapeutics, Inc.
|
$3.47 | $11.74 | $53.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.81 | $0.85 | $228.1M | 3.04x | $0.80 | 0% | 3.52x |
|
NNVC
NanoViricides, Inc.
|
$1.37 | $7.00 | $24.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.99 | $2.00 | $810.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GRCE
Grace Therapeutics, Inc.
|
-- | 1.348 | -- | 13.54x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GRCE
Grace Therapeutics, Inc.
|
-- | -$2.5M | -12.98% | -12.98% | -- | -$3.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Grace Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns GRCE or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Grace Therapeutics, Inc.'s net margin of -255.85%. Grace Therapeutics, Inc.'s return on equity of -12.98% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics, Inc.-- -$0.06 $62.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About GRCE or NBY?
Grace Therapeutics, Inc. has a consensus price target of $11.74, signalling upside risk potential of 238.39%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -53.04%. Given that Grace Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Grace Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is GRCE or NBY More Risky?
Grace Therapeutics, Inc. has a beta of 1.058, which suggesting that the stock is 5.765% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock GRCE or NBY?
Grace Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Grace Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or NBY?
Grace Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Grace Therapeutics, Inc.'s net income of -$938K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Grace Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics, Inc. is -- versus 3.52x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics, Inc.-- -- -- -$938K NBYNovaBay Pharmaceuticals, Inc.3.52x 3.04x $521K -$1.3M
-
Which has Higher Returns GRCE or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Grace Therapeutics, Inc.'s net margin of --. Grace Therapeutics, Inc.'s return on equity of -12.98% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics, Inc.-- -$0.06 $62.8M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About GRCE or NNVC?
Grace Therapeutics, Inc. has a consensus price target of $11.74, signalling upside risk potential of 238.39%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 410.95%. Given that NanoViricides, Inc. has higher upside potential than Grace Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than Grace Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics, Inc.2 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is GRCE or NNVC More Risky?
Grace Therapeutics, Inc. has a beta of 1.058, which suggesting that the stock is 5.765% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock GRCE or NNVC?
Grace Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or NNVC?
Grace Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Grace Therapeutics, Inc.'s net income of -$938K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Grace Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics, Inc.-- -- -- -$938K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns GRCE or OGEN?
Oragenics, Inc. has a net margin of -- compared to Grace Therapeutics, Inc.'s net margin of --. Grace Therapeutics, Inc.'s return on equity of -12.98% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics, Inc.-- -$0.06 $62.8M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About GRCE or OGEN?
Grace Therapeutics, Inc. has a consensus price target of $11.74, signalling upside risk potential of 238.39%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 103.05%. Given that Grace Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Grace Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics, Inc.2 0 0 OGENOragenics, Inc.1 0 0 -
Is GRCE or OGEN More Risky?
Grace Therapeutics, Inc. has a beta of 1.058, which suggesting that the stock is 5.765% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock GRCE or OGEN?
Grace Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or OGEN?
Grace Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Grace Therapeutics, Inc.'s net income of -$938K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Grace Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics, Inc.-- -- -- -$938K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns GRCE or PTN?
Palatin Technologies has a net margin of -- compared to Grace Therapeutics, Inc.'s net margin of --. Grace Therapeutics, Inc.'s return on equity of -12.98% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics, Inc.-- -$0.06 $62.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About GRCE or PTN?
Grace Therapeutics, Inc. has a consensus price target of $11.74, signalling upside risk potential of 238.39%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Grace Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Grace Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is GRCE or PTN More Risky?
Grace Therapeutics, Inc. has a beta of 1.058, which suggesting that the stock is 5.765% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock GRCE or PTN?
Grace Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or PTN?
Grace Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Grace Therapeutics, Inc.'s net income of -$938K is higher than Palatin Technologies's net income of --. Notably, Grace Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics, Inc.-- -- -- -$938K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns GRCE or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Grace Therapeutics, Inc.'s net margin of --. Grace Therapeutics, Inc.'s return on equity of -12.98% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics, Inc.-- -$0.06 $62.8M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About GRCE or TOVX?
Grace Therapeutics, Inc. has a consensus price target of $11.74, signalling upside risk potential of 238.39%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3039.01%. Given that Theriva Biologics, Inc. has higher upside potential than Grace Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Grace Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is GRCE or TOVX More Risky?
Grace Therapeutics, Inc. has a beta of 1.058, which suggesting that the stock is 5.765% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock GRCE or TOVX?
Grace Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or TOVX?
Grace Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Grace Therapeutics, Inc.'s net income of -$938K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Grace Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics, Inc.-- -- -- -$938K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
50
PLAB alert for Dec 10
Photronics, Inc. [PLAB] is up 45.35% over the past day.
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
